Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Apr 28, 2023 6:22pm
210 Views
Post# 35420224

RE:RE:RE:Minority Investor?

RE:RE:RE:Minority Investor?

Your optimistic view makes a lot of sense.
Some have been saying institutions are avoiding Onc for mangement or science reasons.
You are right on the $$ some institutions are restricted from buying below a certain price. The $5 number is one level.
hard to believe some institutions were not considering Ford motor (F), under $10, yet clamouring to buy into the teens & 20s.
That said, there are about 25+ institutions that do own shares of Onc( y).
Still, the trading price is way way out of synchronization with upside potential.
Should the science prove out, then the math becomes.
" what income can future sales of Pelareorep generate".....
THAT will be the cornerstone of a buy- out calculation.
partnership? Same math, the potential partner needs to see the opportunity for a return on investment.
again from the sale of the drug.
Note; The trading share price, as absolutely nothing to do with any if the future income potentials.
That comes from the sale of the drug. 
Once the data comes out,.....assuming it is good activity will based on expectations , elevate the price.
Using your under $5, logic , once at that level, you will see significant movements.
Few, understand the upside speed & bredth of the movements.
being underweight with institutions is actually a great thing! Lots of share for them to become a part of.
Want to make exceptional $$$ on a stock. Find one very much under the radar, with huge upside.
Takes huge patience , balls of steel.
Ironically this weeks notice of a ASCO presentation was discussed, months ago.
Now, the market is reacting like it's something new!
The details being " oral presentation" is new. None the less. The smart $$ was buying last few months.
Just saying
.
 

<< Previous
Bullboard Posts
Next >>